MX2024015750A - Metodos para el tratamiento con mosunetuzumab y lenalidomida del linfoma folicular no tratado previamente - Google Patents
Metodos para el tratamiento con mosunetuzumab y lenalidomida del linfoma folicular no tratado previamenteInfo
- Publication number
- MX2024015750A MX2024015750A MX2024015750A MX2024015750A MX2024015750A MX 2024015750 A MX2024015750 A MX 2024015750A MX 2024015750 A MX2024015750 A MX 2024015750A MX 2024015750 A MX2024015750 A MX 2024015750A MX 2024015750 A MX2024015750 A MX 2024015750A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- mosunetuzumab
- lenalidomide
- previously untreated
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263354491P | 2022-06-22 | 2022-06-22 | |
| PCT/US2023/068804 WO2023250367A1 (en) | 2022-06-22 | 2023-06-21 | Methods for treatment of previously untreated follicular lymphoma with mosunetuzumab and lenalidomide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024015750A true MX2024015750A (es) | 2025-02-10 |
Family
ID=87519897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024015750A MX2024015750A (es) | 2022-06-22 | 2024-12-17 | Metodos para el tratamiento con mosunetuzumab y lenalidomida del linfoma folicular no tratado previamente |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240043553A1 (https=) |
| EP (1) | EP4543546A1 (https=) |
| JP (1) | JP2025521501A (https=) |
| KR (1) | KR20250025678A (https=) |
| CN (1) | CN119546334A (https=) |
| AU (1) | AU2023286618A1 (https=) |
| CA (1) | CA3259327A1 (https=) |
| IL (1) | IL317679A (https=) |
| MX (1) | MX2024015750A (https=) |
| TW (1) | TWI881370B (https=) |
| WO (1) | WO2023250367A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026009843A (ja) * | 2024-06-25 | 2026-01-21 | ジェネンテック， インコーポレイテッド | 単剤療法としてまたはレナリドミドと組み合わせたモスネツズマブの皮下投与を用いてがんを処置する方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CA3190376A1 (en) * | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| JP7716473B2 (ja) * | 2020-11-04 | 2025-07-31 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬 |
| TWI874719B (zh) * | 2020-11-04 | 2025-03-01 | 美商建南德克公司 | 用抗cd20/抗cd3雙特異性抗體進行治療之給藥 |
-
2023
- 2023-06-21 EP EP23748657.6A patent/EP4543546A1/en active Pending
- 2023-06-21 KR KR1020257000914A patent/KR20250025678A/ko active Pending
- 2023-06-21 CA CA3259327A patent/CA3259327A1/en active Pending
- 2023-06-21 JP JP2024574565A patent/JP2025521501A/ja active Pending
- 2023-06-21 CN CN202380047723.4A patent/CN119546334A/zh active Pending
- 2023-06-21 WO PCT/US2023/068804 patent/WO2023250367A1/en not_active Ceased
- 2023-06-21 TW TW112123338A patent/TWI881370B/zh active
- 2023-06-21 US US18/338,985 patent/US20240043553A1/en active Pending
- 2023-06-21 IL IL317679A patent/IL317679A/en unknown
- 2023-06-21 AU AU2023286618A patent/AU2023286618A1/en active Pending
-
2024
- 2024-12-17 MX MX2024015750A patent/MX2024015750A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119546334A (zh) | 2025-02-28 |
| US20240043553A1 (en) | 2024-02-08 |
| KR20250025678A (ko) | 2025-02-24 |
| EP4543546A1 (en) | 2025-04-30 |
| CA3259327A1 (en) | 2023-12-28 |
| AU2023286618A1 (en) | 2025-01-09 |
| IL317679A (en) | 2025-02-01 |
| WO2023250367A1 (en) | 2023-12-28 |
| TWI881370B (zh) | 2025-04-21 |
| TW202409075A (zh) | 2024-03-01 |
| JP2025521501A (ja) | 2025-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024006742A2 (es) | Compuestos terapéuticos para la infección por el virus del vih | |
| CL2023001949A1 (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso (divisional de solicitud de patente no. 3422-2020) | |
| MX2022015272A (es) | Inhibidores de la proteina kras g12c y usos de estos. | |
| CR20190162A (es) | Métodos para usar un anticuerpo biespecífico que reconoce el factor de coagulación ix y/o el factor de coagulación ix activado y el factor de coagulación x y/o el factor de coagulación x activado | |
| MX2024015750A (es) | Metodos para el tratamiento con mosunetuzumab y lenalidomida del linfoma folicular no tratado previamente | |
| BR112022012473A2 (pt) | Composição de tratamento capilar, e, métodos para tratar cabelo, para melhorar a condição do cabelo e para diminuir o ph do cabelo | |
| MX2020011817A (es) | Metodos para tratar el linfoma. | |
| BR112022021562A2 (pt) | Partículas interferentes terapêuticas para o coronavírus | |
| CL2022003511A1 (es) | Inhibidores de alk2 para el tratamiento de la anemia. | |
| MX2024005105A (es) | Metodos para el tratamiento de linfoma folicular recidivante/resistente con mosunetuzumab y lenalidomida. | |
| MX2023000868A (es) | Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo. | |
| CL2019002313A1 (es) | Combinación de cotinina y antioxidante para la resistencia al tratamiento de la depresión y corrección del déficit funcional de los astrocitos inducido por la depresión y otras afecciones neuropatológicas. | |
| MX2024005632A (es) | Tratamiento de la depresion resistente al tratamiento con psilocibina. | |
| CL2024001351A1 (es) | Composiciones y tratamientos con nirogacestat | |
| CO2023002828A2 (es) | Composición insecticida sinérgica | |
| BR112022008183A2 (pt) | Formas de sal de um receptor de c5a de componente do complemento | |
| MX2024010980A (es) | Formas polimórficas de aticaprant para usar en el tratamiento del trastorno depresivo mayor | |
| CL2023003777A1 (es) | Métodos de tratamiento con moduladores del receptor de esfingosina-1-fosfato (s1p) | |
| MX2019001412A (es) | Compuestos de 9-aminometil minociclina y usos de los mismos. | |
| MX2022012506A (es) | Métodos y medios para modificar la hemodinámica en infecciones. | |
| MX2025002938A (es) | Formas fisicas de un inhibidor de prc2 | |
| MX2021009488A (es) | Uso de vibegron para tratar la vejiga hiperactiva. | |
| MX2023014898A (es) | Terapia combinada anti-vhc ventajosa. | |
| CO2023007133A2 (es) | Compuesto degradante en un medicamento | |
| MX2023004034A (es) | Métodos de tratamiento de la dermatomiositis. |